Sanofi's blockbuster eczema drug trial failed — and wiped $13B off the stock

Sanofi, the French pharmaceutical giant headquartered in Paris, spent years developing amlitelimab, an experimental antibody targeting OX40 ligand for atopic dermatitis (eczema) and other inflammatory diseases. The drug was considered one of the company's most important pipeline assets, with analysts projecting blockbuster sales if approved.

In September 2025, Sanofi announced results from the Phase III trials for amlitelimab in atopic dermatitis. While the trials met their primary and key secondary endpoints, the efficacy data fell short of analyst expectations and was weaker than the Phase II results that had generated the initial enthusiasm. Investors reacted sharply — Sanofi shares dropped more than 10% in a single day, wiping out nearly $13 billion in market capitalization.

The failure was particularly damaging because Sanofi had structured much of its pipeline strategy around amlitelimab as a follow-up to Dupixent, its blockbuster eczema drug that faced patent expiration. The weaker-than-expected data raised questions about whether amlitelimab could compete in a crowded inflammatory disease market that included established players and other novel mechanisms.

Sanofi bet its pipeline on amlitelimab as Dupixent's successor, but weaker-than-expected efficacy data triggered a 10% stock drop and $13B market cap loss.

Sanofi bet its mid-term pipeline on amlitelimab as the successor to Dupixent, concentrating too much R&D hope on a single candidate without sufficient diversification.

The Phase III data failed to replicate the strength of Phase II results — an efficacy gap from trials too small or homogeneous to predict real-world performance.

Sanofi had no backup plan for the inflammatory disease pipeline, so the failure left a multi-billion-dollar revenue hole as Dupixent approached patent expiry.

The market reaction was amplified by Sanofi's already-stretched valuation, which had priced in amlitelimab's success as a certainty rather than a risk.

Betting your pipeline on one drug is betting on one point of failure. Between blockbuster and write-off is a single trial — no early promise changes that.